Mario Saltarelli, MD, PhD
About Us
Current Events
Past Events
Video Gallery
Policy & Reports
Media Coverage
Contact Us
Mario Saltarelli, MD, PhD
Chief Medical Officer
Entrada Therapeutics

Mario Saltarelli, MD, PhD is the Chief Medical Officer of Entrada Therapeutics, a biotechnology company focused on the treatment of devastating diseases through the intracellular delivery of biologics.

Dr. Saltarelli recently served as Executive Vice-President and Chief Medical Officer at Syntimmune, where he progressed the company’s rare autoimmune disease pipeline. Syntimmune was acquired by Alexion in November 2018. For more than two decades prior to Syntimmune, Dr. Saltarelli led research and development organizations at a number of pharmaceutical and biotechnology companies, including Pfizer, Abbott, Shire, Mallinckrodt, Annexon and Vertex.

During his career he has led and/or contributed to more than 100 drug development programs, including the marketed products CHANTIX® (varenicline; smoking cessation), DUOPATM (carbidopa/levodopa; Parkinson’s disease), DEPAKOTE® (valproate; epilepsy, bipolar disease, migraine), VYVANSE® (lisdexamfetamine; ADHD, binge eating disorder) and SYMDEKO® (tezacaftor/ivacaftor; cystic fibrosis).

Dr. Saltarelli holds MD and PhD (neuroscience) degrees from The Johns Hopkins University School of Medicine. He completed clinical residency training at The Johns Hopkins Hospital and served as Assistant Professor of Neurology at Emory University School of Medicine prior to entering the pharmaceutical industry. Dr. Saltarelli has contributed to more than 100 publications and patents during his career.

© 2007 - USA India Chamber of Commerce Home | About us | Policy | Events | Photo Gallery | Awards | Media Coverage | Legal | Contact us